Sex differences in clinical features of early, treated Parkinson's disease

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Augustine, Erika F ^a   Pérez, Adriana ^b   Dhall, Rohit ^c   Umeh, Chizoba C ^d   Videnovic, Aleksandar ^d   Cambi, Franca ^e   Wills, Anne Marie A ^d   Elm, Jordan J ^f   Zweig, Richard M ^g   Shulman, Lisa M ^h   Nance, Martha A ⁱ   Bainbridge, Jacquelyn ^j   Suchowersky, Oksana ^k  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^h UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

ⁱ Louisiana State University Health Sciences Center ^*  (United States)

^j UNIVERSITY OF COLORADO   (United States)

^k UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; LEVODOPA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DYSTONIA; EDUCATION; EUROQOL 5 D UTILITY SCORE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; KOLMOGOROV SMIRNOV TEST; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MIDDLE AGED; MULTICENTER STUDY; NEUROBIOLOGY; PARKINSON DISEASE; PARKINSON DISEASE QUESTIONNAIRE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RATING SCALE; SEX DIFFERENCE; SYMPTOMATOLOGY; UNIFIED PARKINSON DISEASE RATING SCALE; VERY ELDERLY; CLINICAL TRIAL; METABOLISM; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SEXUAL DEVELOPMENT;

ADULT; AGED; AGED, 80 AND OVER; CREATINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS;

EID: 84940509416     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133002     Document Type: Article

References (43)

1. Irvine K, Laws KR, Gale TM, Kondel TK. Greater cognitive deterioration in women than men with Alzheimer's disease: a meta analysis. J Clin Exp Neuropsychol. 2012; 34 (9):989-98. Epub 2012/08/24. doi: 10.1080/13803395.2012.712676 PMID: 22913619.
2. Kehoe P, Krawczak M, Harper PS, Owen MJ, Jones AL. Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet. 1999; 36 (2):108-11. Epub 1999/03/02. PMID: 10051007; PubMed Central PMCID: PMC1734310.
3. Cialone J, Adams H, Augustine EF, Marshall FJ, Kwon JM, Newhouse N, et al. Females experience a more severe disease course in Batten disease. J Inherit Metab Dis. 2012; 35(3):549-55. Epub 2011/ 12/15. doi: 10.1007/s10545-011-9421-6 PMID: 22167274; PubMed Central PMCID: PMCPMC3320704.
4. Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008; 7 (10):915-26. Epub 2008/08/30. doi: 10.1016/s1474-4422(08)70193-5 PMID: 18722812; PubMed Central PMCID: PMC2665267.
5. Towfighi A, Zheng L, Ovbiagele B. Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med. 2009; 169(19):1762-6. Epub 2009/10/28. doi: 10.1001/archinternmed.2009. 318 PMID: 19858433.
6. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex Disparities in Treatment of Cardiac Risk Factors in Patients With Type 2 Diabetes. Diabetes Care. 2005; 28(3):514-20. doi: 10.2337/diacare. 28.3.514 PMID: 15735180
7. National Institutes of Health Revitalization Act of 1993, Subtitle B-Clinical Research Equity Regarding Women and Minorities, Part I-Women and Minorities as Subjects in Clinical Research. 1993.
8. NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research- Amended, October, 2001 [April 4, 2014]. Available from: http://grants1.nih.gov/grants/funding/women-min/guidelines-amended-10-2001.htm.
9. Exploring the biological contributions to human health: does sex matter? J Womens Health Gend Based Med. 2001; 10(5):433-9. Epub 2001/07/11. doi: 10.1089/152460901300233902 PMID: 11445042.
10. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006; 5(6):525-35. Epub 2006/05/23. doi: 10.1016/s1474-4422(06)70471-9 PMID: 16713924.
11. Alves G, Muller B, Herlofson K, HogenEsch I, Telstad W, Aarsland D, et al. Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2009; 80(8):851-7. Epub 2009/02/28. doi: 10.1136/jnnp.2008.168211 PMID: 19246476.
12. Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology. 2000; 55(9):1358-63. Epub 2000/11/23. PMID: 11087781.
13. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003; 157 (11):1015-22. Epub 2003/06/05. PMID: 12777365.
14. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry. 2004; 75(4):637-9. Epub 2004/03/18. PMID: 15026515; PubMed Central PMCID: PMC1739032.
15. Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ. 2000; 321(7252):21-2. Epub 2000/06/30. PMID: 10875828; PubMed Central PMCID: PMC27420.
16. Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol. 2014; 113(3):485-90. Epub 2013/12/10. doi: 10.1016/j. amjcard.2013.10.035 PMID: 24315113.
17. Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov. 2006; 5(5):425-38. Epub 2006/05/05. doi: 10.1038/nrd2032 PMID: 16672926.
18. Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol. 2008; 83:1-10. Epub 2008/10/22. doi: 10.1016/s0074-7742(08)00001-9 PMID: 18929073.
19. Elm JJ, NINDS NET-PD Investigators. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 2012; 27(12):1513-21. Epub 2012/10/20. doi: 10.1002/mds. 25175 PMID: 23079770; PubMed Central PMCID: PMC3481179.
20. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators. Effect of creatine monohydrate on clinical progression in patients with parkinson disease: A randomized clinical trial. JAMA. 2015; 313(6):584-93. doi: 10.1001/jama.2015.120 PMID: 25668262
21. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007; 68(5):384-6. Epub 2006/11/04. doi: 10.1212/01.wnl.0000247740.47667.03 PMID: 17082464.
22. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov Disord. 2013; 28(3):311-8. Epub 2013/02/26. doi: 10. 1002/mds.25292 PMID: 23436720.
23. Amantea D, Russo R, Bagetta G, Corasaniti MT. From clinical evidence to molecular mechanisms underlying neuroprotection afforded by estrogens. Pharmacol Res. 2005; 52(2):119-32. Epub 2005/ 06/22. doi: 10.1016/j.phrs.2005.03.002 PMID: 15967377
24. Brann DW, Dhandapani K, Wakade C, Mahesh VB, Khan MM. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids. 2007; 72(5):381-405. Epub 2007/03/24. doi: 10.1016/j.steroids.2007.02.003 PMID: 17379265; PubMed Central PMCID: PMC2048656.
25. Bourque M, Dluzen DE, Di Paolo T. Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease. Front Neuroendocrinol. 2012; 33(2):169-78. Epub 2012/ 03/06. doi: 10.1016/j.yfrne.2012.02.003 PMID: 22387674.
26. Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, et al. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007; 78(8):819-24. Epub 2006/11/14. doi: 10.1136/ jnnp.2006.103788 PMID: 17098842; PubMed Central PMCID: PMC2117736.
27. Baba Y, Putzke JD, Whaley NR, Wszolek ZK, Uitti RJ. Gender and the Parkinson's disease phenotype. J Neurol. 2005; 252(10):1201-5. Epub 2005/09/10. doi: 10.1007/s00415-005-0835-7 PMID: 16151602.
28. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology. 1990; 40(5):763-6. Epub 1990/05/01. PMID: 2330103.
29. Martinez-Martin P, Falup Pecurariu C, Odin P, van Hilten JJ, Antonini A, Rojo-Abuin JM, et al. Genderrelated differences in the burden of non-motor symptoms in Parkinson's disease. J Neurol. 2012; 259 (8):1639-47. Epub 2012/01/13. doi: 10.1007/s00415-011-6392-3 PMID: 22237822.
30. Lyons KE, Hubble JP, Troster AI, Pahwa R, Koller WC. Gender differences in Parkinson's disease. Clin Neuropharmacol. 1998; 21(2):118-21. Epub 1998/05/14. PMID: 9579298.
31. Saunders-Pullman R, Wang C, Stanley K, Bressman SB. Diagnosis and referral delay in women with Parkinson's disease. PMID: Gend Med. 2011; 8(3):209-17. Epub 2011/06/15. doi: 10.1016/j.genm. 2011.05.002 PMID: 21664587.
32. Solla P, Cannas A, Ibba FC, Loi F, Corona M, Orofino G, et al. Gender differences in motor and nonmotor symptoms among Sardinian patients with Parkinson's disease. J Neurol Sci. 2012; 323(1-2):33-9. Epub 2012/09/01. doi: 10.1016/j.jns.2012.07.026 PMID: 22935408.
33. Stavitsky K, Cronin-Golomb A. Sleep quality in Parkinson disease: an examination of clinical variables. Cogn Behav Neurol. 2011; 24(2):43-9. Epub 2011/05/04. doi: 10.1097/WNN.0b013e31821a4a95 PMID: 21537164; PubMed Central PMCID: PMC3126883.
34. Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, Bertram M, et al. Mutations in the gene encoding [epsiv]-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet. 2001; 29(1):66-9. http://www.nature.com/ng/journal/v29/n1/suppinfo/ng709-S1.html. PMID: 11528394
35. van der Hoek TC, Bus BA, Matui P, van der Marck MA, Esselink RA, Tendolkar I. Prevalence of depression in Parkinson's disease: effects of disease stage, motor subtype and gender. J Neurol Sci. 2011; 310(1-2):220-4. Epub 2011/08/02. doi: 10.1016/j.jns.2011.07.007 PMID: 21802694.
36. Rana AQ, Yousuf MS, Naz S, Qa'aty N. Prevalence and relation of dementia to various factors in Parkinson's disease. Psychiatry Clin Neurosci. 2012; 66(1):64-8. Epub 2012/01/19. doi: 10.1111/j.1440- 1819.2011.02291.x PMID: 22250611.
37. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology. 2000; 54(8):1596-602. Epub 2000/04/13. PMID: 10762499.
38. Roos RA, Jongen JC, van der Velde EA. Clinical course of patients with idiopathic Parkinson's disease. Mov Disord. 1996; 11(3):236-42. Epub 1996/05/01. doi: 10.1002/mds.870110304 PMID: 8723138.
39. Umeh CC, Perez A, Augustine EF, Dhall R, Dewey RB Jr., Mari Z, et al. No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada-baseline findings of a multicenter trial. PLoS One. 2014; 9(12):e112287. Epub 2014/12/09. doi: 10.1371/journal.pone. 0112287 PMID: 25486269; PubMed Central PMCID: PMC4259292.
40. Munro CA, Winicki JM, Schretlen DJ, Gower EW, Turano KA, Munoz B, et al. Sex differences in cognition in healthy elderly individuals. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2012; 19 (6):759-68. Epub 2012/06/08. doi: 10.1080/13825585.2012.690366 PMID: 22670852; PubMed Central PMCID: PMC3518851.
41. Jorm AF, Anstey KJ, Christensen H, Rodgers B. Gender differences in cognitive abilities: The mediating role of health state and health habits. Intelligence. 2004; 32(1):7-23. http://dx.doi.org/10.1016/j. intell.2003.08.001.
42. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord. 2006; 21(8):1200-7. Epub 2006/05/05. doi: 10.1002/mds. 20914 PMID: 16673410.
43. Leroi I, McDonald K, Pantula H, Harbishettar V. Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psychiatry Neurol. 2012; 25(4):208-14. Epub 2012/11/23. doi: 10.1177/0891988712464823 PMID: 23172765.